ArticleFrontiers in pharmacology2025

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient.

Kaili Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.